Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2055

Sort by

Sort Order Select

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Blood (2020) 135 (13): 1071.

https://doi.org/10.1182/blood.2020005086

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 926.

https://doi.org/10.1182/blood-2019-125871

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin

Blood (2019) 134 (Supplement_1): 930.

https://doi.org/10.1182/blood-2019-130340

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Naoyuki Tange, MD, Fumihiko Hayakawa, MD, PhD, Takahiko Yasuda, MD, PhD, Hideyuki Yamamoto, MD, Daiki Hirano, MD, PhD, Shinobu Tsuzuki, MD,PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 1349.

https://doi.org/10.1182/blood-2019-123602

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 1541.

https://doi.org/10.1182/blood-2019-127494

Published: 2019

Journal Articles

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Tara K. Gregory, MD, Suman Kambhampati, MD, Bertrand M. Anz, III, MD, Stefano R. Tarantolo, MD, Anthony A. Meluch, MD, Jeffrey V. Matous, MD

Blood (2019) 134 (Supplement_1): 603.

https://doi.org/10.1182/blood-2019-130277

Published: 2019

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Kiwamu Hatakeyama, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 631.

https://doi.org/10.1182/blood-2019-125670

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

AL patients don’t dare go without dara

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only